Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today ...
An international, randomized, double-blind, placebo-controlled Phase III study—the largest of its kind for mpox—found that ...
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. This is an ...
Pivotal study shows no clear benefit for the common endoscopic procedure in this patient group. Experts say the new data ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients ...
Among six trials that analyzed outcomes for nearly 20,000 participants by sex, women lost an average of 10.88% (95% CI -14.76 to -7) of their baseline body weight on a GLP-1 agent, while men lost 6.8% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results